nodes	percent_of_prediction	percent_of_DWPC	metapath
Rosuvastatin—CYP3A4—bone cancer	0.335	1	CbGaD
Rosuvastatin—ABCC1—Epirubicin—bone cancer	0.0785	0.134	CbGbCtD
Rosuvastatin—ABCB11—Doxorubicin—bone cancer	0.0587	0.101	CbGbCtD
Rosuvastatin—SLCO1B3—Methotrexate—bone cancer	0.0584	0.1	CbGbCtD
Rosuvastatin—ABCC4—Methotrexate—bone cancer	0.0503	0.0862	CbGbCtD
Rosuvastatin—ABCG2—Carboplatin—bone cancer	0.0487	0.0835	CbGbCtD
Rosuvastatin—ABCC1—Doxorubicin—bone cancer	0.0417	0.0715	CbGbCtD
Rosuvastatin—ABCG2—Cisplatin—bone cancer	0.0416	0.0714	CbGbCtD
Rosuvastatin—ABCC1—Methotrexate—bone cancer	0.0404	0.0692	CbGbCtD
Rosuvastatin—SLCO1A2—Methotrexate—bone cancer	0.0361	0.0618	CbGbCtD
Rosuvastatin—SLCO1B1—Methotrexate—bone cancer	0.034	0.0583	CbGbCtD
Rosuvastatin—ABCG2—Doxorubicin—bone cancer	0.0279	0.0478	CbGbCtD
Rosuvastatin—ABCG2—Methotrexate—bone cancer	0.027	0.0463	CbGbCtD
Rosuvastatin—ALB—Methotrexate—bone cancer	0.0186	0.0319	CbGbCtD
Rosuvastatin—CYP2C9—Cisplatin—bone cancer	0.0155	0.0265	CbGbCtD
Rosuvastatin—CYP3A4—Doxorubicin—bone cancer	0.00603	0.0103	CbGbCtD
Rosuvastatin—Memory loss—Cisplatin—bone cancer	0.00223	0.0618	CcSEcCtD
Rosuvastatin—Cognitive impairment—Methotrexate—bone cancer	0.00138	0.0382	CcSEcCtD
Rosuvastatin—SLCO2B1—Farnesoid X Receptor  Pathway—CYP3A4—bone cancer	0.00129	0.0287	CbGpPWpGaD
Rosuvastatin—SLCO1B1—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.00126	0.0281	CbGpPWpGaD
Rosuvastatin—ABCG2—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00117	0.026	CbGpPWpGaD
Rosuvastatin—ABCB11—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.00103	0.023	CbGpPWpGaD
Rosuvastatin—ABCB11—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00102	0.0226	CbGpPWpGaD
Rosuvastatin—ABCB11—Farnesoid X Receptor  Pathway—CYP3A4—bone cancer	0.000945	0.0211	CbGpPWpGaD
Rosuvastatin—ABCC4—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000931	0.0207	CbGpPWpGaD
Rosuvastatin—ABCC1—Irinotecan Pathway—CYP3A4—bone cancer	0.000906	0.0202	CbGpPWpGaD
Rosuvastatin—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00089	0.0198	CbGpPWpGaD
Rosuvastatin—SLCO1B1—Irinotecan Pathway—CYP3A4—bone cancer	0.000861	0.0192	CbGpPWpGaD
Rosuvastatin—Cognitive disorder—Methotrexate—bone cancer	0.000831	0.023	CcSEcCtD
Rosuvastatin—ABCG2—Irinotecan Pathway—CYP3A4—bone cancer	0.000797	0.0178	CbGpPWpGaD
Rosuvastatin—Infection—Carboplatin—bone cancer	0.000791	0.0219	CcSEcCtD
Rosuvastatin—Nephropathy—Methotrexate—bone cancer	0.000755	0.0209	CcSEcCtD
Rosuvastatin—SLCO1B1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000737	0.0164	CbGpPWpGaD
Rosuvastatin—ABCC1—Sphingosine 1-phosphate (S1P) pathway—GNA11—bone cancer	0.000723	0.0161	CbGpPWpGaD
Rosuvastatin—Fluvastatin—CYP3A4—bone cancer	0.000713	1	CrCbGaD
Rosuvastatin—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000688	0.0153	CbGpPWpGaD
Rosuvastatin—Myositis—Epirubicin—bone cancer	0.000686	0.019	CcSEcCtD
Rosuvastatin—Pain—Carboplatin—bone cancer	0.000681	0.0189	CcSEcCtD
Rosuvastatin—ABCC4—Ectoderm Differentiation—BCOR—bone cancer	0.000668	0.0149	CbGpPWpGaD
Rosuvastatin—ABCC4—Fluoropyrimidine Activity—DHFR—bone cancer	0.000646	0.0144	CbGpPWpGaD
Rosuvastatin—Myositis—Doxorubicin—bone cancer	0.000635	0.0176	CcSEcCtD
Rosuvastatin—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000627	0.014	CbGpPWpGaD
Rosuvastatin—ALB—Folate Metabolism—FOLR1—bone cancer	0.000612	0.0136	CbGpPWpGaD
Rosuvastatin—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.0006	0.0134	CbGpPWpGaD
Rosuvastatin—ABCB11—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000593	0.0132	CbGpPWpGaD
Rosuvastatin—Urine analysis abnormal—Epirubicin—bone cancer	0.000572	0.0159	CcSEcCtD
Rosuvastatin—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000571	0.0127	CbGpPWpGaD
Rosuvastatin—Urine analysis abnormal—Doxorubicin—bone cancer	0.000529	0.0147	CcSEcCtD
Rosuvastatin—Renal failure acute—Cisplatin—bone cancer	0.000515	0.0143	CcSEcCtD
Rosuvastatin—Amnesia—Cisplatin—bone cancer	0.000506	0.014	CcSEcCtD
Rosuvastatin—ABCG2—Fluoropyrimidine Activity—DHFR—bone cancer	0.000474	0.0106	CbGpPWpGaD
Rosuvastatin—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000447	0.00997	CbGpPWpGaD
Rosuvastatin—Breast disorder—Cisplatin—bone cancer	0.00043	0.0119	CcSEcCtD
Rosuvastatin—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000429	0.00957	CbGpPWpGaD
Rosuvastatin—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000414	0.00922	CbGpPWpGaD
Rosuvastatin—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000413	0.00921	CbGpPWpGaD
Rosuvastatin—Proteinuria—Methotrexate—bone cancer	0.000409	0.0113	CcSEcCtD
Rosuvastatin—Protein urine present—Methotrexate—bone cancer	0.000403	0.0112	CcSEcCtD
Rosuvastatin—Pancreatitis—Cisplatin—bone cancer	0.000403	0.0112	CcSEcCtD
Rosuvastatin—Blood disorder—Epirubicin—bone cancer	0.000403	0.0112	CcSEcCtD
Rosuvastatin—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000389	0.00868	CbGpPWpGaD
Rosuvastatin—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000383	0.00854	CbGpPWpGaD
Rosuvastatin—Hepatic enzyme increased—Methotrexate—bone cancer	0.00038	0.0105	CcSEcCtD
Rosuvastatin—Blood disorder—Doxorubicin—bone cancer	0.000373	0.0103	CcSEcCtD
Rosuvastatin—Cough increased—Epirubicin—bone cancer	0.000367	0.0102	CcSEcCtD
Rosuvastatin—Neuropathy peripheral—Cisplatin—bone cancer	0.000359	0.00995	CcSEcCtD
Rosuvastatin—Hepatobiliary disease—Cisplatin—bone cancer	0.000347	0.0096	CcSEcCtD
Rosuvastatin—Cough increased—Doxorubicin—bone cancer	0.00034	0.00942	CcSEcCtD
Rosuvastatin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000339	0.00756	CbGpPWpGaD
Rosuvastatin—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000332	0.0074	CbGpPWpGaD
Rosuvastatin—ABCC4—Platelet degranulation—SPARC—bone cancer	0.000325	0.00725	CbGpPWpGaD
Rosuvastatin—Gynaecomastia—Methotrexate—bone cancer	0.000322	0.00891	CcSEcCtD
Rosuvastatin—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000319	0.00712	CbGpPWpGaD
Rosuvastatin—ABCC1—S1P1 pathway—PTGS2—bone cancer	0.000314	0.00701	CbGpPWpGaD
Rosuvastatin—ABCC4—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.00031	0.00691	CbGpPWpGaD
Rosuvastatin—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000303	0.00675	CbGpPWpGaD
Rosuvastatin—Diabetes mellitus—Methotrexate—bone cancer	0.0003	0.00831	CcSEcCtD
Rosuvastatin—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000296	0.0066	CbGpPWpGaD
Rosuvastatin—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000295	0.00657	CbGpPWpGaD
Rosuvastatin—Hypertonia—Epirubicin—bone cancer	0.000295	0.00817	CcSEcCtD
Rosuvastatin—Arrhythmia—Cisplatin—bone cancer	0.000294	0.00814	CcSEcCtD
Rosuvastatin—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000291	0.00649	CbGpPWpGaD
Rosuvastatin—Hepatic failure—Methotrexate—bone cancer	0.00029	0.00805	CcSEcCtD
Rosuvastatin—SLC7A11—NRF2 pathway—TGFBR2—bone cancer	0.000289	0.00643	CbGpPWpGaD
Rosuvastatin—SLC7A11—NRF2 pathway—GSTP1—bone cancer	0.000289	0.00643	CbGpPWpGaD
Rosuvastatin—Renal failure acute—Methotrexate—bone cancer	0.000283	0.00783	CcSEcCtD
Rosuvastatin—Flatulence—Cisplatin—bone cancer	0.000282	0.00782	CcSEcCtD
Rosuvastatin—Diabetes mellitus—Epirubicin—bone cancer	0.000281	0.00778	CcSEcCtD
Rosuvastatin—Hypertonia—Doxorubicin—bone cancer	0.000273	0.00756	CcSEcCtD
Rosuvastatin—Hepatic failure—Epirubicin—bone cancer	0.000272	0.00753	CcSEcCtD
Rosuvastatin—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.00027	0.00602	CbGpPWpGaD
Rosuvastatin—Renal failure acute—Epirubicin—bone cancer	0.000264	0.00733	CcSEcCtD
Rosuvastatin—Diabetes mellitus—Doxorubicin—bone cancer	0.00026	0.0072	CcSEcCtD
Rosuvastatin—HMGCR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000255	0.00569	CbGpPWpGaD
Rosuvastatin—Hepatic failure—Doxorubicin—bone cancer	0.000251	0.00697	CcSEcCtD
Rosuvastatin—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000251	0.0056	CbGpPWpGaD
Rosuvastatin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000248	0.00553	CbGpPWpGaD
Rosuvastatin—HMGCR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000246	0.00547	CbGpPWpGaD
Rosuvastatin—Renal failure acute—Doxorubicin—bone cancer	0.000245	0.00678	CcSEcCtD
Rosuvastatin—Myalgia—Cisplatin—bone cancer	0.000244	0.00676	CcSEcCtD
Rosuvastatin—Breast disorder—Methotrexate—bone cancer	0.000236	0.00653	CcSEcCtD
Rosuvastatin—Infection—Cisplatin—bone cancer	0.000232	0.00643	CcSEcCtD
Rosuvastatin—Nervous system disorder—Cisplatin—bone cancer	0.000229	0.00635	CcSEcCtD
Rosuvastatin—Thrombocytopenia—Cisplatin—bone cancer	0.000229	0.00634	CcSEcCtD
Rosuvastatin—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000228	0.00508	CbGpPWpGaD
Rosuvastatin—SLC7A11—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000227	0.00506	CbGpPWpGaD
Rosuvastatin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000224	0.00498	CbGpPWpGaD
Rosuvastatin—Pancreatitis—Methotrexate—bone cancer	0.000221	0.00613	CcSEcCtD
Rosuvastatin—Breast disorder—Epirubicin—bone cancer	0.000221	0.00611	CcSEcCtD
Rosuvastatin—Muscular weakness—Epirubicin—bone cancer	0.000215	0.00597	CcSEcCtD
Rosuvastatin—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000213	0.0059	CcSEcCtD
Rosuvastatin—HMGCR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000213	0.00475	CbGpPWpGaD
Rosuvastatin—Influenza—Epirubicin—bone cancer	0.000211	0.00585	CcSEcCtD
Rosuvastatin—Paraesthesia—Cisplatin—bone cancer	0.00021	0.00582	CcSEcCtD
Rosuvastatin—HMGCR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000208	0.00464	CbGpPWpGaD
Rosuvastatin—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000208	0.00463	CbGpPWpGaD
Rosuvastatin—Pancreatitis—Epirubicin—bone cancer	0.000207	0.00573	CcSEcCtD
Rosuvastatin—Breast disorder—Doxorubicin—bone cancer	0.000204	0.00566	CcSEcCtD
Rosuvastatin—Bronchitis—Epirubicin—bone cancer	0.000203	0.00562	CcSEcCtD
Rosuvastatin—Depression—Methotrexate—bone cancer	0.0002	0.00556	CcSEcCtD
Rosuvastatin—Pain—Cisplatin—bone cancer	0.0002	0.00554	CcSEcCtD
Rosuvastatin—Muscular weakness—Doxorubicin—bone cancer	0.000199	0.00552	CcSEcCtD
Rosuvastatin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000198	0.00441	CbGpPWpGaD
Rosuvastatin—SLC7A11—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000196	0.00437	CbGpPWpGaD
Rosuvastatin—Influenza—Doxorubicin—bone cancer	0.000195	0.00541	CcSEcCtD
Rosuvastatin—Feeling abnormal—Cisplatin—bone cancer	0.000193	0.00534	CcSEcCtD
Rosuvastatin—Haematuria—Methotrexate—bone cancer	0.000192	0.00531	CcSEcCtD
Rosuvastatin—Pancreatitis—Doxorubicin—bone cancer	0.000191	0.00531	CcSEcCtD
Rosuvastatin—Hepatobiliary disease—Methotrexate—bone cancer	0.00019	0.00527	CcSEcCtD
Rosuvastatin—Bronchitis—Doxorubicin—bone cancer	0.000188	0.0052	CcSEcCtD
Rosuvastatin—Neuropathy peripheral—Epirubicin—bone cancer	0.000184	0.00511	CcSEcCtD
Rosuvastatin—Jaundice—Epirubicin—bone cancer	0.000183	0.00508	CcSEcCtD
Rosuvastatin—Urinary tract infection—Epirubicin—bone cancer	0.000183	0.00507	CcSEcCtD
Rosuvastatin—Hepatitis—Methotrexate—bone cancer	0.00018	0.005	CcSEcCtD
Rosuvastatin—Haematuria—Epirubicin—bone cancer	0.000179	0.00497	CcSEcCtD
Rosuvastatin—Pharyngitis—Methotrexate—bone cancer	0.000179	0.00496	CcSEcCtD
Rosuvastatin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000178	0.00398	CbGpPWpGaD
Rosuvastatin—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000178	0.00397	CbGpPWpGaD
Rosuvastatin—Hepatobiliary disease—Epirubicin—bone cancer	0.000178	0.00493	CcSEcCtD
Rosuvastatin—Sinusitis—Epirubicin—bone cancer	0.000177	0.00489	CcSEcCtD
Rosuvastatin—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000176	0.00392	CbGpPWpGaD
Rosuvastatin—Hypersensitivity—Cisplatin—bone cancer	0.000172	0.00477	CcSEcCtD
Rosuvastatin—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000171	0.00381	CbGpPWpGaD
Rosuvastatin—Neuropathy peripheral—Doxorubicin—bone cancer	0.000171	0.00473	CcSEcCtD
Rosuvastatin—Jaundice—Doxorubicin—bone cancer	0.00017	0.0047	CcSEcCtD
Rosuvastatin—Rhinitis—Epirubicin—bone cancer	0.000169	0.00469	CcSEcCtD
Rosuvastatin—Urinary tract infection—Doxorubicin—bone cancer	0.000169	0.00469	CcSEcCtD
Rosuvastatin—SLCO2B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000169	0.00377	CbGpPWpGaD
Rosuvastatin—Hepatitis—Epirubicin—bone cancer	0.000169	0.00468	CcSEcCtD
Rosuvastatin—ALB—Folate Metabolism—DHFR—bone cancer	0.000168	0.00374	CbGpPWpGaD
Rosuvastatin—Asthenia—Cisplatin—bone cancer	0.000168	0.00465	CcSEcCtD
Rosuvastatin—Pharyngitis—Epirubicin—bone cancer	0.000168	0.00465	CcSEcCtD
Rosuvastatin—Haematuria—Doxorubicin—bone cancer	0.000166	0.0046	CcSEcCtD
Rosuvastatin—Hepatobiliary disease—Doxorubicin—bone cancer	0.000165	0.00456	CcSEcCtD
Rosuvastatin—Sinusitis—Doxorubicin—bone cancer	0.000163	0.00453	CcSEcCtD
Rosuvastatin—Diarrhoea—Cisplatin—bone cancer	0.00016	0.00443	CcSEcCtD
Rosuvastatin—Mental disorder—Methotrexate—bone cancer	0.000158	0.00438	CcSEcCtD
Rosuvastatin—Rhinitis—Doxorubicin—bone cancer	0.000157	0.00434	CcSEcCtD
Rosuvastatin—Hepatitis—Doxorubicin—bone cancer	0.000156	0.00433	CcSEcCtD
Rosuvastatin—Pharyngitis—Doxorubicin—bone cancer	0.000155	0.0043	CcSEcCtD
Rosuvastatin—HMGCR—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000154	0.00344	CbGpPWpGaD
Rosuvastatin—Arrhythmia—Epirubicin—bone cancer	0.000151	0.00418	CcSEcCtD
Rosuvastatin—SLC7A11—Hemostasis—SPARC—bone cancer	0.000151	0.00336	CbGpPWpGaD
Rosuvastatin—Mental disorder—Epirubicin—bone cancer	0.000148	0.0041	CcSEcCtD
Rosuvastatin—Rash—Cisplatin—bone cancer	0.000147	0.00408	CcSEcCtD
Rosuvastatin—Dermatitis—Cisplatin—bone cancer	0.000147	0.00408	CcSEcCtD
Rosuvastatin—ALB—Platelet degranulation—SPARC—bone cancer	0.000147	0.00328	CbGpPWpGaD
Rosuvastatin—SLCO2B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000146	0.00325	CbGpPWpGaD
Rosuvastatin—ABCC1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000145	0.00323	CbGpPWpGaD
Rosuvastatin—Flatulence—Epirubicin—bone cancer	0.000145	0.00402	CcSEcCtD
Rosuvastatin—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000145	0.00322	CbGpPWpGaD
Rosuvastatin—ABCC4—Fluoropyrimidine Activity—TP53—bone cancer	0.000144	0.00322	CbGpPWpGaD
Rosuvastatin—ABCC4—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000144	0.00322	CbGpPWpGaD
Rosuvastatin—ABCC4—NRF2 pathway—TGFBR2—bone cancer	0.000143	0.00318	CbGpPWpGaD
Rosuvastatin—ABCC4—NRF2 pathway—GSTP1—bone cancer	0.000143	0.00318	CbGpPWpGaD
Rosuvastatin—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.00014	0.00312	CbGpPWpGaD
Rosuvastatin—Arrhythmia—Doxorubicin—bone cancer	0.00014	0.00387	CcSEcCtD
Rosuvastatin—Nausea—Cisplatin—bone cancer	0.000139	0.00385	CcSEcCtD
Rosuvastatin—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000138	0.00307	CbGpPWpGaD
Rosuvastatin—SLC7A11—Hemostasis—GNA11—bone cancer	0.000138	0.00307	CbGpPWpGaD
Rosuvastatin—Cough—Methotrexate—bone cancer	0.000137	0.0038	CcSEcCtD
Rosuvastatin—Mental disorder—Doxorubicin—bone cancer	0.000137	0.00379	CcSEcCtD
Rosuvastatin—HMGCR—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000137	0.00304	CbGpPWpGaD
Rosuvastatin—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000136	0.00303	CbGpPWpGaD
Rosuvastatin—HMGCR—Metabolism—NDUFA12—bone cancer	0.000134	0.003	CbGpPWpGaD
Rosuvastatin—HMGCR—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000134	0.00299	CbGpPWpGaD
Rosuvastatin—Flatulence—Doxorubicin—bone cancer	0.000134	0.00372	CcSEcCtD
Rosuvastatin—Arthralgia—Methotrexate—bone cancer	0.000134	0.00371	CcSEcCtD
Rosuvastatin—Myalgia—Methotrexate—bone cancer	0.000134	0.00371	CcSEcCtD
Rosuvastatin—SLCO1B3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000132	0.00294	CbGpPWpGaD
Rosuvastatin—ABCC4—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000132	0.00294	CbGpPWpGaD
Rosuvastatin—Confusional state—Methotrexate—bone cancer	0.000129	0.00358	CcSEcCtD
Rosuvastatin—Cough—Epirubicin—bone cancer	0.000128	0.00356	CcSEcCtD
Rosuvastatin—Infection—Methotrexate—bone cancer	0.000127	0.00353	CcSEcCtD
Rosuvastatin—Nervous system disorder—Methotrexate—bone cancer	0.000126	0.00349	CcSEcCtD
Rosuvastatin—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000126	0.0028	CbGpPWpGaD
Rosuvastatin—Thrombocytopenia—Methotrexate—bone cancer	0.000126	0.00348	CcSEcCtD
Rosuvastatin—Arthralgia—Epirubicin—bone cancer	0.000125	0.00347	CcSEcCtD
Rosuvastatin—Myalgia—Epirubicin—bone cancer	0.000125	0.00347	CcSEcCtD
Rosuvastatin—SLC7A11—Hemostasis—IL3—bone cancer	0.000125	0.00278	CbGpPWpGaD
Rosuvastatin—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000124	0.00277	CbGpPWpGaD
Rosuvastatin—HMGCR—AMPK Signaling—TP53—bone cancer	0.000123	0.00274	CbGpPWpGaD
Rosuvastatin—Confusional state—Epirubicin—bone cancer	0.000121	0.00335	CcSEcCtD
Rosuvastatin—ABCC4—Platelet activation, signaling and aggregation—IL3—bone cancer	0.00012	0.00267	CbGpPWpGaD
Rosuvastatin—Infection—Epirubicin—bone cancer	0.000119	0.0033	CcSEcCtD
Rosuvastatin—Cough—Doxorubicin—bone cancer	0.000119	0.00329	CcSEcCtD
Rosuvastatin—Nervous system disorder—Epirubicin—bone cancer	0.000118	0.00326	CcSEcCtD
Rosuvastatin—Thrombocytopenia—Epirubicin—bone cancer	0.000117	0.00326	CcSEcCtD
Rosuvastatin—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000117	0.00324	CcSEcCtD
Rosuvastatin—Insomnia—Methotrexate—bone cancer	0.000116	0.00321	CcSEcCtD
Rosuvastatin—Myalgia—Doxorubicin—bone cancer	0.000116	0.00321	CcSEcCtD
Rosuvastatin—Arthralgia—Doxorubicin—bone cancer	0.000116	0.00321	CcSEcCtD
Rosuvastatin—Paraesthesia—Methotrexate—bone cancer	0.000115	0.00319	CcSEcCtD
Rosuvastatin—HMGCR—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000114	0.00255	CbGpPWpGaD
Rosuvastatin—SLCO1B3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000114	0.00254	CbGpPWpGaD
Rosuvastatin—Dyspepsia—Methotrexate—bone cancer	0.000113	0.00313	CcSEcCtD
Rosuvastatin—ABCC4—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000112	0.0025	CbGpPWpGaD
Rosuvastatin—Confusional state—Doxorubicin—bone cancer	0.000112	0.0031	CcSEcCtD
Rosuvastatin—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000112	0.00249	CbGpPWpGaD
Rosuvastatin—HMGCR—Metabolism—NT5C3A—bone cancer	0.000111	0.00248	CbGpPWpGaD
Rosuvastatin—Infection—Doxorubicin—bone cancer	0.00011	0.00306	CcSEcCtD
Rosuvastatin—Pain—Methotrexate—bone cancer	0.00011	0.00304	CcSEcCtD
Rosuvastatin—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000109	0.00303	CcSEcCtD
Rosuvastatin—Nervous system disorder—Doxorubicin—bone cancer	0.000109	0.00302	CcSEcCtD
Rosuvastatin—Thrombocytopenia—Doxorubicin—bone cancer	0.000109	0.00301	CcSEcCtD
Rosuvastatin—Insomnia—Epirubicin—bone cancer	0.000109	0.00301	CcSEcCtD
Rosuvastatin—Paraesthesia—Epirubicin—bone cancer	0.000108	0.00299	CcSEcCtD
Rosuvastatin—ABCG2—Fluoropyrimidine Activity—TP53—bone cancer	0.000106	0.00236	CbGpPWpGaD
Rosuvastatin—Feeling abnormal—Methotrexate—bone cancer	0.000106	0.00293	CcSEcCtD
Rosuvastatin—Dyspepsia—Epirubicin—bone cancer	0.000106	0.00293	CcSEcCtD
Rosuvastatin—Gastrointestinal pain—Methotrexate—bone cancer	0.000105	0.00291	CcSEcCtD
Rosuvastatin—SLCO1A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000104	0.00231	CbGpPWpGaD
Rosuvastatin—SLCO1B3—Metabolism—NDUFA12—bone cancer	0.000103	0.0023	CbGpPWpGaD
Rosuvastatin—Constipation—Epirubicin—bone cancer	0.000103	0.00284	CcSEcCtD
Rosuvastatin—Pain—Epirubicin—bone cancer	0.000103	0.00284	CcSEcCtD
Rosuvastatin—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000102	0.00227	CbGpPWpGaD
Rosuvastatin—Urticaria—Methotrexate—bone cancer	0.000102	0.00282	CcSEcCtD
Rosuvastatin—Abdominal pain—Methotrexate—bone cancer	0.000101	0.00281	CcSEcCtD
Rosuvastatin—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000101	0.0028	CcSEcCtD
Rosuvastatin—Insomnia—Doxorubicin—bone cancer	0.0001	0.00278	CcSEcCtD
Rosuvastatin—Paraesthesia—Doxorubicin—bone cancer	9.97e-05	0.00276	CcSEcCtD
Rosuvastatin—HMGCR—Integrated Breast Cancer Pathway—JUN—bone cancer	9.94e-05	0.00222	CbGpPWpGaD
Rosuvastatin—Feeling abnormal—Epirubicin—bone cancer	9.89e-05	0.00274	CcSEcCtD
Rosuvastatin—Gastrointestinal pain—Epirubicin—bone cancer	9.81e-05	0.00272	CcSEcCtD
Rosuvastatin—Dyspepsia—Doxorubicin—bone cancer	9.77e-05	0.00271	CcSEcCtD
Rosuvastatin—ABCB11—Metabolism—NDUFA12—bone cancer	9.72e-05	0.00217	CbGpPWpGaD
Rosuvastatin—ABCC4—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.67e-05	0.00216	CbGpPWpGaD
Rosuvastatin—Urticaria—Epirubicin—bone cancer	9.53e-05	0.00264	CcSEcCtD
Rosuvastatin—Pain—Doxorubicin—bone cancer	9.5e-05	0.00263	CcSEcCtD
Rosuvastatin—Constipation—Doxorubicin—bone cancer	9.5e-05	0.00263	CcSEcCtD
Rosuvastatin—Abdominal pain—Epirubicin—bone cancer	9.49e-05	0.00263	CcSEcCtD
Rosuvastatin—Hypersensitivity—Methotrexate—bone cancer	9.45e-05	0.00262	CcSEcCtD
Rosuvastatin—ABCC1—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.34e-05	0.00208	CbGpPWpGaD
Rosuvastatin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	9.31e-05	0.00208	CbGpPWpGaD
Rosuvastatin—ABCG2—HIF-1-alpha transcription factor network—JUN—bone cancer	9.21e-05	0.00205	CbGpPWpGaD
Rosuvastatin—Asthenia—Methotrexate—bone cancer	9.2e-05	0.00255	CcSEcCtD
Rosuvastatin—Feeling abnormal—Doxorubicin—bone cancer	9.15e-05	0.00254	CcSEcCtD
Rosuvastatin—Gastrointestinal pain—Doxorubicin—bone cancer	9.08e-05	0.00252	CcSEcCtD
Rosuvastatin—Pruritus—Methotrexate—bone cancer	9.07e-05	0.00251	CcSEcCtD
Rosuvastatin—SLCO1A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.96e-05	0.002	CbGpPWpGaD
Rosuvastatin—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.87e-05	0.00198	CbGpPWpGaD
Rosuvastatin—Hypersensitivity—Epirubicin—bone cancer	8.84e-05	0.00245	CcSEcCtD
Rosuvastatin—Urticaria—Doxorubicin—bone cancer	8.82e-05	0.00244	CcSEcCtD
Rosuvastatin—Abdominal pain—Doxorubicin—bone cancer	8.78e-05	0.00243	CcSEcCtD
Rosuvastatin—Diarrhoea—Methotrexate—bone cancer	8.77e-05	0.00243	CcSEcCtD
Rosuvastatin—Asthenia—Epirubicin—bone cancer	8.61e-05	0.00239	CcSEcCtD
Rosuvastatin—SLCO1B3—Metabolism—NT5C3A—bone cancer	8.56e-05	0.00191	CbGpPWpGaD
Rosuvastatin—Pruritus—Epirubicin—bone cancer	8.49e-05	0.00235	CcSEcCtD
Rosuvastatin—Dizziness—Methotrexate—bone cancer	8.48e-05	0.00235	CcSEcCtD
Rosuvastatin—ABCG2—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.22e-05	0.00183	CbGpPWpGaD
Rosuvastatin—Diarrhoea—Epirubicin—bone cancer	8.21e-05	0.00228	CcSEcCtD
Rosuvastatin—SLC7A11—Hemostasis—PLAU—bone cancer	8.19e-05	0.00183	CbGpPWpGaD
Rosuvastatin—Hypersensitivity—Doxorubicin—bone cancer	8.18e-05	0.00227	CcSEcCtD
Rosuvastatin—SLCO1A2—Metabolism—NDUFA12—bone cancer	8.11e-05	0.00181	CbGpPWpGaD
Rosuvastatin—Rash—Methotrexate—bone cancer	8.09e-05	0.00224	CcSEcCtD
Rosuvastatin—Dermatitis—Methotrexate—bone cancer	8.08e-05	0.00224	CcSEcCtD
Rosuvastatin—ABCC1—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.06e-05	0.0018	CbGpPWpGaD
Rosuvastatin—ABCB11—Metabolism—NT5C3A—bone cancer	8.05e-05	0.0018	CbGpPWpGaD
Rosuvastatin—Headache—Methotrexate—bone cancer	8.03e-05	0.00223	CcSEcCtD
Rosuvastatin—Asthenia—Doxorubicin—bone cancer	7.97e-05	0.00221	CcSEcCtD
Rosuvastatin—Dizziness—Epirubicin—bone cancer	7.94e-05	0.0022	CcSEcCtD
Rosuvastatin—Pruritus—Doxorubicin—bone cancer	7.86e-05	0.00218	CcSEcCtD
Rosuvastatin—HMGCR—Integrated Breast Cancer Pathway—EGFR—bone cancer	7.82e-05	0.00174	CbGpPWpGaD
Rosuvastatin—CYP3A5—Biological oxidations—CYP3A4—bone cancer	7.68e-05	0.00171	CbGpPWpGaD
Rosuvastatin—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.66e-05	0.00171	CbGpPWpGaD
Rosuvastatin—Nausea—Methotrexate—bone cancer	7.62e-05	0.00211	CcSEcCtD
Rosuvastatin—Diarrhoea—Doxorubicin—bone cancer	7.6e-05	0.00211	CcSEcCtD
Rosuvastatin—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	7.57e-05	0.00169	CbGpPWpGaD
Rosuvastatin—Rash—Epirubicin—bone cancer	7.57e-05	0.0021	CcSEcCtD
Rosuvastatin—Dermatitis—Epirubicin—bone cancer	7.56e-05	0.00209	CcSEcCtD
Rosuvastatin—Headache—Epirubicin—bone cancer	7.52e-05	0.00208	CcSEcCtD
Rosuvastatin—ABCC4—Hemostasis—SPARC—bone cancer	7.43e-05	0.00166	CbGpPWpGaD
Rosuvastatin—Dizziness—Doxorubicin—bone cancer	7.34e-05	0.00203	CcSEcCtD
Rosuvastatin—ABCC1—Metabolism—NDUFA12—bone cancer	7.3e-05	0.00163	CbGpPWpGaD
Rosuvastatin—Nausea—Epirubicin—bone cancer	7.13e-05	0.00198	CcSEcCtD
Rosuvastatin—ABCG2—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.09e-05	0.00158	CbGpPWpGaD
Rosuvastatin—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	7.07e-05	0.00158	CbGpPWpGaD
Rosuvastatin—Rash—Doxorubicin—bone cancer	7e-05	0.00194	CcSEcCtD
Rosuvastatin—Dermatitis—Doxorubicin—bone cancer	6.99e-05	0.00194	CcSEcCtD
Rosuvastatin—Headache—Doxorubicin—bone cancer	6.96e-05	0.00193	CcSEcCtD
Rosuvastatin—SLCO1B1—Metabolism—NDUFA12—bone cancer	6.94e-05	0.00155	CbGpPWpGaD
Rosuvastatin—ABCC4—Hemostasis—GNA11—bone cancer	6.8e-05	0.00152	CbGpPWpGaD
Rosuvastatin—SLCO1A2—Metabolism—NT5C3A—bone cancer	6.72e-05	0.0015	CbGpPWpGaD
Rosuvastatin—Nausea—Doxorubicin—bone cancer	6.6e-05	0.00183	CcSEcCtD
Rosuvastatin—CYP3A5—Biological oxidations—GSTP1—bone cancer	6.57e-05	0.00146	CbGpPWpGaD
Rosuvastatin—HMGCR—Integrated Breast Cancer Pathway—TP53—bone cancer	6.56e-05	0.00146	CbGpPWpGaD
Rosuvastatin—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	6.53e-05	0.00145	CbGpPWpGaD
Rosuvastatin—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	6.48e-05	0.00144	CbGpPWpGaD
Rosuvastatin—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	6.44e-05	0.00144	CbGpPWpGaD
Rosuvastatin—ABCG2—Metabolism—NDUFA12—bone cancer	6.42e-05	0.00143	CbGpPWpGaD
Rosuvastatin—ABCC4—Hemostasis—IL3—bone cancer	6.16e-05	0.00137	CbGpPWpGaD
Rosuvastatin—ABCC1—Metabolism—NT5C3A—bone cancer	6.05e-05	0.00135	CbGpPWpGaD
Rosuvastatin—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	5.97e-05	0.00133	CbGpPWpGaD
Rosuvastatin—CYP2C19—Biological oxidations—CYP3A4—bone cancer	5.94e-05	0.00132	CbGpPWpGaD
Rosuvastatin—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	5.86e-05	0.00131	CbGpPWpGaD
Rosuvastatin—SLCO1B1—Metabolism—NT5C3A—bone cancer	5.75e-05	0.00128	CbGpPWpGaD
Rosuvastatin—CYP2C9—Biological oxidations—CYP3A4—bone cancer	5.41e-05	0.00121	CbGpPWpGaD
Rosuvastatin—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	5.41e-05	0.00121	CbGpPWpGaD
Rosuvastatin—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	5.34e-05	0.00119	CbGpPWpGaD
Rosuvastatin—ABCG2—Metabolism—NT5C3A—bone cancer	5.32e-05	0.00119	CbGpPWpGaD
Rosuvastatin—CYP2C19—Biological oxidations—GSTP1—bone cancer	5.08e-05	0.00113	CbGpPWpGaD
Rosuvastatin—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	5.07e-05	0.00113	CbGpPWpGaD
Rosuvastatin—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	5.01e-05	0.00112	CbGpPWpGaD
Rosuvastatin—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	5.01e-05	0.00112	CbGpPWpGaD
Rosuvastatin—HMGCR—Metabolism—ENO2—bone cancer	4.88e-05	0.00109	CbGpPWpGaD
Rosuvastatin—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	4.71e-05	0.00105	CbGpPWpGaD
Rosuvastatin—CYP2C9—Biological oxidations—GSTP1—bone cancer	4.63e-05	0.00103	CbGpPWpGaD
Rosuvastatin—CYP3A5—Metabolism—NDUFA12—bone cancer	4.6e-05	0.00103	CbGpPWpGaD
Rosuvastatin—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	4.57e-05	0.00102	CbGpPWpGaD
Rosuvastatin—HMGCR—Metabolism—DHFR—bone cancer	4.53e-05	0.00101	CbGpPWpGaD
Rosuvastatin—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.38e-05	0.000976	CbGpPWpGaD
Rosuvastatin—HMGCR—Metabolism—GNA11—bone cancer	4.23e-05	0.000943	CbGpPWpGaD
Rosuvastatin—ABCC4—Hemostasis—PLAU—bone cancer	4.04e-05	0.000901	CbGpPWpGaD
Rosuvastatin—ALB—Metabolism—NDUFA12—bone cancer	3.96e-05	0.000884	CbGpPWpGaD
Rosuvastatin—HMGCR—Metabolism—CYP3A4—bone cancer	3.84e-05	0.000855	CbGpPWpGaD
Rosuvastatin—HMGCR—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.82e-05	0.000851	CbGpPWpGaD
Rosuvastatin—CYP3A5—Metabolism—NT5C3A—bone cancer	3.81e-05	0.00085	CbGpPWpGaD
Rosuvastatin—ALB—Folate Metabolism—TP53—bone cancer	3.75e-05	0.000837	CbGpPWpGaD
Rosuvastatin—SLCO1B3—Metabolism—ENO2—bone cancer	3.75e-05	0.000836	CbGpPWpGaD
Rosuvastatin—CYP2C19—Metabolism—NDUFA12—bone cancer	3.56e-05	0.000793	CbGpPWpGaD
Rosuvastatin—ABCB11—Metabolism—ENO2—bone cancer	3.53e-05	0.000786	CbGpPWpGaD
Rosuvastatin—SLCO1B3—Metabolism—DHFR—bone cancer	3.48e-05	0.000775	CbGpPWpGaD
Rosuvastatin—ALB—Hemostasis—SPARC—bone cancer	3.36e-05	0.00075	CbGpPWpGaD
Rosuvastatin—SLC7A11—Hemostasis—TP53—bone cancer	3.29e-05	0.000734	CbGpPWpGaD
Rosuvastatin—ALB—Metabolism—NT5C3A—bone cancer	3.28e-05	0.000732	CbGpPWpGaD
Rosuvastatin—HMGCR—Metabolism—GSTP1—bone cancer	3.28e-05	0.000731	CbGpPWpGaD
Rosuvastatin—ABCB11—Metabolism—DHFR—bone cancer	3.27e-05	0.000729	CbGpPWpGaD
Rosuvastatin—SLCO1B3—Metabolism—GNA11—bone cancer	3.25e-05	0.000724	CbGpPWpGaD
Rosuvastatin—CYP2C9—Metabolism—NDUFA12—bone cancer	3.24e-05	0.000723	CbGpPWpGaD
Rosuvastatin—ABCC1—Disease—ENO2—bone cancer	3.16e-05	0.000705	CbGpPWpGaD
Rosuvastatin—ALB—Hemostasis—GNA11—bone cancer	3.08e-05	0.000686	CbGpPWpGaD
Rosuvastatin—ABCB11—Metabolism—GNA11—bone cancer	3.06e-05	0.000682	CbGpPWpGaD
Rosuvastatin—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.05e-05	0.000681	CbGpPWpGaD
Rosuvastatin—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.01e-05	0.000671	CbGpPWpGaD
Rosuvastatin—CYP2C19—Metabolism—NT5C3A—bone cancer	2.95e-05	0.000657	CbGpPWpGaD
Rosuvastatin—SLCO1B3—Metabolism—CYP3A4—bone cancer	2.95e-05	0.000657	CbGpPWpGaD
Rosuvastatin—SLCO1A2—Metabolism—ENO2—bone cancer	2.94e-05	0.000656	CbGpPWpGaD
Rosuvastatin—ABCC1—Disease—DHFR—bone cancer	2.94e-05	0.000654	CbGpPWpGaD
Rosuvastatin—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.93e-05	0.000653	CbGpPWpGaD
Rosuvastatin—ALB—Hemostasis—IL3—bone cancer	2.79e-05	0.000622	CbGpPWpGaD
Rosuvastatin—ABCB11—Metabolism—CYP3A4—bone cancer	2.77e-05	0.000618	CbGpPWpGaD
Rosuvastatin—ABCB11—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.76e-05	0.000615	CbGpPWpGaD
Rosuvastatin—SLCO1A2—Metabolism—DHFR—bone cancer	2.73e-05	0.000609	CbGpPWpGaD
Rosuvastatin—CYP2C9—Metabolism—NT5C3A—bone cancer	2.69e-05	0.000599	CbGpPWpGaD
Rosuvastatin—ABCC1—Metabolism—ENO2—bone cancer	2.65e-05	0.000591	CbGpPWpGaD
Rosuvastatin—SLCO1A2—Metabolism—GNA11—bone cancer	2.55e-05	0.000569	CbGpPWpGaD
Rosuvastatin—SLCO1B3—Metabolism—GSTP1—bone cancer	2.52e-05	0.000562	CbGpPWpGaD
Rosuvastatin—SLCO1B1—Metabolism—ENO2—bone cancer	2.52e-05	0.000561	CbGpPWpGaD
Rosuvastatin—ABCC1—Metabolism—DHFR—bone cancer	2.46e-05	0.000548	CbGpPWpGaD
Rosuvastatin—ABCB11—Metabolism—GSTP1—bone cancer	2.37e-05	0.000529	CbGpPWpGaD
Rosuvastatin—SLCO1B1—Metabolism—DHFR—bone cancer	2.34e-05	0.000521	CbGpPWpGaD
Rosuvastatin—ABCG2—Metabolism—ENO2—bone cancer	2.33e-05	0.00052	CbGpPWpGaD
Rosuvastatin—SLCO1A2—Metabolism—CYP3A4—bone cancer	2.31e-05	0.000516	CbGpPWpGaD
Rosuvastatin—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.3e-05	0.000513	CbGpPWpGaD
Rosuvastatin—ABCC1—Metabolism—GNA11—bone cancer	2.3e-05	0.000512	CbGpPWpGaD
Rosuvastatin—SLCO1B1—Metabolism—GNA11—bone cancer	2.18e-05	0.000487	CbGpPWpGaD
Rosuvastatin—ABCG2—Metabolism—DHFR—bone cancer	2.16e-05	0.000482	CbGpPWpGaD
Rosuvastatin—CYP3A4—Metabolism—NDUFA12—bone cancer	2.14e-05	0.000477	CbGpPWpGaD
Rosuvastatin—ABCC1—Disease—TGFBR2—bone cancer	2.13e-05	0.000474	CbGpPWpGaD
Rosuvastatin—ABCC1—Metabolism—CYP3A4—bone cancer	2.08e-05	0.000464	CbGpPWpGaD
Rosuvastatin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.07e-05	0.000462	CbGpPWpGaD
Rosuvastatin—ABCG2—Metabolism—GNA11—bone cancer	2.02e-05	0.000451	CbGpPWpGaD
Rosuvastatin—SLCO1A2—Metabolism—GSTP1—bone cancer	1.98e-05	0.000441	CbGpPWpGaD
Rosuvastatin—SLCO1B1—Metabolism—CYP3A4—bone cancer	1.98e-05	0.000441	CbGpPWpGaD
Rosuvastatin—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.97e-05	0.000439	CbGpPWpGaD
Rosuvastatin—ABCG2—Metabolism—CYP3A4—bone cancer	1.83e-05	0.000409	CbGpPWpGaD
Rosuvastatin—ALB—Hemostasis—PLAU—bone cancer	1.83e-05	0.000408	CbGpPWpGaD
Rosuvastatin—ABCC1—Metabolism—GSTP1—bone cancer	1.78e-05	0.000397	CbGpPWpGaD
Rosuvastatin—CYP3A4—Metabolism—NT5C3A—bone cancer	1.77e-05	0.000395	CbGpPWpGaD
Rosuvastatin—HMGCR—Metabolism—PTGS2—bone cancer	1.7e-05	0.000379	CbGpPWpGaD
Rosuvastatin—SLCO1B1—Metabolism—GSTP1—bone cancer	1.69e-05	0.000377	CbGpPWpGaD
Rosuvastatin—CYP3A5—Metabolism—ENO2—bone cancer	1.67e-05	0.000372	CbGpPWpGaD
Rosuvastatin—ABCC4—Hemostasis—TP53—bone cancer	1.63e-05	0.000362	CbGpPWpGaD
Rosuvastatin—ABCG2—Metabolism—GSTP1—bone cancer	1.57e-05	0.000349	CbGpPWpGaD
Rosuvastatin—CYP3A5—Metabolism—DHFR—bone cancer	1.55e-05	0.000346	CbGpPWpGaD
Rosuvastatin—ABCC1—Disease—KIT—bone cancer	1.45e-05	0.000324	CbGpPWpGaD
Rosuvastatin—CYP3A5—Metabolism—GNA11—bone cancer	1.45e-05	0.000323	CbGpPWpGaD
Rosuvastatin—ALB—Metabolism—ENO2—bone cancer	1.44e-05	0.000321	CbGpPWpGaD
Rosuvastatin—ABCC1—Disease—BRAF—bone cancer	1.36e-05	0.000304	CbGpPWpGaD
Rosuvastatin—ALB—Metabolism—DHFR—bone cancer	1.33e-05	0.000298	CbGpPWpGaD
Rosuvastatin—CYP3A5—Metabolism—CYP3A4—bone cancer	1.31e-05	0.000293	CbGpPWpGaD
Rosuvastatin—SLCO1B3—Metabolism—PTGS2—bone cancer	1.31e-05	0.000291	CbGpPWpGaD
Rosuvastatin—CYP2C19—Metabolism—ENO2—bone cancer	1.29e-05	0.000288	CbGpPWpGaD
Rosuvastatin—ALB—Metabolism—GNA11—bone cancer	1.25e-05	0.000278	CbGpPWpGaD
Rosuvastatin—ABCB11—Metabolism—PTGS2—bone cancer	1.23e-05	0.000274	CbGpPWpGaD
Rosuvastatin—CYP2C19—Metabolism—DHFR—bone cancer	1.2e-05	0.000267	CbGpPWpGaD
Rosuvastatin—CYP2C9—Metabolism—ENO2—bone cancer	1.18e-05	0.000263	CbGpPWpGaD
Rosuvastatin—ABCC1—Disease—MDM2—bone cancer	1.14e-05	0.000255	CbGpPWpGaD
Rosuvastatin—ALB—Metabolism—CYP3A4—bone cancer	1.13e-05	0.000252	CbGpPWpGaD
Rosuvastatin—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.13e-05	0.000251	CbGpPWpGaD
Rosuvastatin—CYP3A5—Metabolism—GSTP1—bone cancer	1.12e-05	0.00025	CbGpPWpGaD
Rosuvastatin—CYP2C19—Metabolism—GNA11—bone cancer	1.12e-05	0.00025	CbGpPWpGaD
Rosuvastatin—ABCC1—Disease—PTGS2—bone cancer	1.1e-05	0.000246	CbGpPWpGaD
Rosuvastatin—CYP2C9—Metabolism—DHFR—bone cancer	1.09e-05	0.000244	CbGpPWpGaD
Rosuvastatin—SLCO1A2—Metabolism—PTGS2—bone cancer	1.03e-05	0.000229	CbGpPWpGaD
Rosuvastatin—CYP2C9—Metabolism—GNA11—bone cancer	1.02e-05	0.000228	CbGpPWpGaD
Rosuvastatin—CYP2C19—Metabolism—CYP3A4—bone cancer	1.02e-05	0.000226	CbGpPWpGaD
Rosuvastatin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.01e-05	0.000225	CbGpPWpGaD
Rosuvastatin—ALB—Metabolism—GSTP1—bone cancer	9.67e-06	0.000216	CbGpPWpGaD
Rosuvastatin—CYP2C9—Metabolism—CYP3A4—bone cancer	9.26e-06	0.000206	CbGpPWpGaD
Rosuvastatin—ABCC1—Metabolism—PTGS2—bone cancer	9.23e-06	0.000206	CbGpPWpGaD
Rosuvastatin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.21e-06	0.000205	CbGpPWpGaD
Rosuvastatin—SLCO1B1—Metabolism—PTGS2—bone cancer	8.77e-06	0.000196	CbGpPWpGaD
Rosuvastatin—CYP2C19—Metabolism—GSTP1—bone cancer	8.68e-06	0.000194	CbGpPWpGaD
Rosuvastatin—ABCG2—Metabolism—PTGS2—bone cancer	8.12e-06	0.000181	CbGpPWpGaD
Rosuvastatin—CYP2C9—Metabolism—GSTP1—bone cancer	7.92e-06	0.000176	CbGpPWpGaD
Rosuvastatin—ABCC1—Disease—EGFR—bone cancer	7.81e-06	0.000174	CbGpPWpGaD
Rosuvastatin—CYP3A4—Metabolism—ENO2—bone cancer	7.77e-06	0.000173	CbGpPWpGaD
Rosuvastatin—ALB—Hemostasis—TP53—bone cancer	7.36e-06	0.000164	CbGpPWpGaD
Rosuvastatin—CYP3A4—Metabolism—DHFR—bone cancer	7.21e-06	0.000161	CbGpPWpGaD
Rosuvastatin—CYP3A4—Metabolism—GNA11—bone cancer	6.73e-06	0.00015	CbGpPWpGaD
Rosuvastatin—CYP3A5—Metabolism—PTGS2—bone cancer	5.82e-06	0.00013	CbGpPWpGaD
Rosuvastatin—CYP3A4—Metabolism—GSTP1—bone cancer	5.22e-06	0.000116	CbGpPWpGaD
Rosuvastatin—ALB—Metabolism—PTGS2—bone cancer	5.01e-06	0.000112	CbGpPWpGaD
Rosuvastatin—CYP2C19—Metabolism—PTGS2—bone cancer	4.5e-06	0.0001	CbGpPWpGaD
Rosuvastatin—CYP2C9—Metabolism—PTGS2—bone cancer	4.1e-06	9.14e-05	CbGpPWpGaD
Rosuvastatin—CYP3A4—Metabolism—PTGS2—bone cancer	2.71e-06	6.03e-05	CbGpPWpGaD
